CLASSIC (GPA and MPA)

Full Name: A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Study Dates: 2014-2018
NCT #: NCT02222155
Study Findings: The goal of the CCX168 development program in ANCA-associated vasculitis (AAV) was to reduce or eliminate the use of chronic high dose glucocorticosteroids (steroids) in current standard of care treatment. This study demonstrated that the study drug CCX168 (avacopan) was well tolerated in patients with AAV when added to current standard of care treatment. This study led to a Phase 3 study called ADVOCATE (listed below).